Investing.com -- U.S. pharmaceutical company Eli Lilly (NYSE: LLY) has introduced its diabetes and weight-loss drug Mounjaro ...

Men's big-and-tall retailer DXL is expecting, perhaps ironically, to benefit from the popularity of GLP-1 drugs such as ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

At STAT's Breakthrough Summit East, the CEOs of Ro and Included Health said the the U.S. health care system poses obstacles ...

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Viking Therapeutics seems to be doubling down on its hopes of making waves in the weight management market as a stand-alone ...

Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and ...